Botulinum toxin type A + Placebo

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Glabellar Lines

Conditions

Glabellar Lines

Trial Timeline

Apr 1, 2015 → Dec 1, 2016

NCT ID

NCT02493946

About Botulinum toxin type A + Placebo

Botulinum toxin type A + Placebo is a phase 3 stage product being developed by Ipsen for Glabellar Lines. The current trial status is completed. This product is registered under clinical trial identifier NCT02493946. Target conditions include Glabellar Lines.

What happened to similar drugs?

0 of 10 similar drugs in Glabellar Lines were approved

Approved (0) Terminated (0) Active (10)

🔄Placebo + AGN-151586AbbViePhase 3

🔄AGN-151586 + PlaceboAbbViePhase 3

🔄AGN-151586AbbViePhase 3

🔄Botulinum toxin type A + Botulinum toxin type A + Placebo + PlaceboIpsenPhase 3

🔄IPN10200 + PlaceboIpsenPhase 3

🔄Botulinum toxin type A + PlaceboIpsenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03569098	Phase 2	Completed	Jun 19, 2018	May 22, 2020	Hallux Abducto Valgus
NCT03598777	Phase 2	Terminated	Jun 11, 2018	Jan 21, 2021	Vulvodynia
NCT02493946	Phase 3	Completed	Apr 1, 2015	Dec 1, 2016	Glabellar Lines
NCT02353871	Phase 3	Completed	Jan 1, 2015	Aug 1, 2015	Moderate to Severe Glabellar Lines
NCT02321436	Approved	Completed	Dec 1, 2014	Mar 1, 2016	Stroke
NCT01753310	Phase 3	Completed	Jan 1, 2013	Jan 1, 2015	Cervical Dystonia
NCT01249417	Phase 3	Completed	Jul 1, 2011	Jun 1, 2014	Cerebral Palsy
NCT01357980	Phase 2	Completed	May 1, 2011	Mar 1, 2013	Detrusor Muscle Hyperactivity
NCT01249404	Phase 3	Completed	Mar 1, 2011	May 1, 2014	Leg Spasticity
NCT00578097	Phase 2	Terminated	Feb 1, 2008	Dec 1, 2009	Overactive Bladder
NCT00257660	Phase 3	Completed	Oct 10, 2005	Sep 1, 2006	Cervical Dystonia
NCT00447876	Phase 2/3	Completed	Jul 1, 2005	Apr 1, 2009	Chronic Plantar Fasciitis
NCT00216411	Approved	Completed	Nov 1, 2004	Jul 20, 2006	Cerebrovascular Accident
NCT00234546	Approved	Completed	Feb 1, 2003	Oct 1, 2007	Muscle Spasticity

Competing Products

19 competing products in Glabellar Lines

See all competitors

Product	Company	Stage	Hype Score
AGN-151586 + BOTOX + Placebo	AbbVie	Phase 1	29
Placebo + AGN-151586	AbbVie	Phase 3	40
AGN-151586 + Placebo	AbbVie	Phase 3	40
AGN-151586 + OnabotulinumtoxinA + Placebo	AbbVie	Phase 1	29
AGN-151586 + Placebo	AbbVie	Phase 3	40
AGN-151586	AbbVie	Phase 3	40
AGN-151586 + Placebo	AbbVie	Phase 1	29
Botulinum toxin type A + Botulinum toxin type A + Placebo + Placebo	Ipsen	Phase 3	37
IPN10200 + Placebo	Ipsen	Phase 3	44
Botulinum toxin type A + Botulinum toxin type A + Placebo	Ipsen	Phase 2	32
Botulinum toxin type A + Placebo	Ipsen	Phase 3	37
IPN10200 + Placebo	Ipsen	Phase 3	44
prabotulinumtoxinA	Evolus	Pre-clinical	20
PrabotulinumtoxinA-Xvfs + OnabotulinumtoxinA + PrabotulinumtoxinA-Xvfs	Evolus	Phase 2	25
Botulinum toxin, Type A	Evolus	Phase 3	30
DWP-450 (Botulinum purified neurotoxin, Type A)	Evolus	Phase 2	25
Botulinum toxin, Type A	Evolus	Phase 3	30
Botulinum purified neurotoxin, Type A	Evolus	Phase 2	25
prabotulinumtoxinA	Evolus	Phase 1	19